PDTM-25. GENETIC SUSCEPTIBILITY AND EVOLUTION OF PEDIATRIC IDH-MUTANT INFILTRATING ASTROCYTOMAS
Bornhorst M, Goecks J, Boue D, Broniscer A, Hwang E, Koschmann C, Marks A, Mody R, Mueller S, Orr B, Packer R, Solomon D, Turner J, Vortmeyer A, Nazarian J, Ho C. PDTM-25. GENETIC SUSCEPTIBILITY AND EVOLUTION OF PEDIATRIC IDH-MUTANT INFILTRATING ASTROCYTOMAS. Neuro-Oncology 2017, 19: vi195-vi195. PMCID: PMC5692642, DOI: 10.1093/neuonc/nox168.789.Peer-Reviewed Original ResearchTP53 mutationsPediatric gliomasGermline mutationsIDH mutationsLow-grade tumorsHigh-grade tumorsLow mutation burdenYears of ageHigh-grade astrocytomasGermline TP53 mutationsMismatch repair genesIDH-mutant astrocytomasYounger patientsMulti-institution studyEarly lesionsMutation burdenMutant allele frequencyPatientsSporadic casesAstrocytomasTumorsSporadic tumorsAdult counterpartsGenetic susceptibilityLow cellularitySOX2 as a target for immunotherapy of pediatric gliomas.
Vasquez J, Huttner A, Zhang L, Marks A, Chan A, Baehring J, Kahle K, Dhodapkar K. SOX2 as a target for immunotherapy of pediatric gliomas. Journal Of Clinical Oncology 2017, 35: e22012-e22012. DOI: 10.1200/jco.2017.35.15_suppl.e22012.Peer-Reviewed Original ResearchTumor-infiltrating T cellsImmune checkpoint blockadeT cellsPediatric glial tumorsGlial tumorsExpression of SOX2Inhibitory checkpointsCheckpoint blockadeTumor immunityGrade gliomasTissue-resident memory phenotypePediatric gliomasTumor-infiltrating immune cellsTumor cellsResident memory phenotypeT-cell proliferation assaysImmune checkpoint inhibitorsDendritic cell vaccinesPD-1 expressionSubset of CD4Anti-tumor immunityCD8 T cellsT cell immunityEffective tumor immunityPediatric brain tumors